Cognixion ALS BCI Longitudinal Study
Cognixion's ALS BCI Longitudinal Study aims to refine the usability of its augmented reality brain-computer interface (BCI) for late-stage ALS patients, a demographic with significant unmet needs in assistive communication. The study's focus on user experience and the effectiveness of alternate input modalities positions Cognixion to potentially capture a niche market within the assistive technology sector. Given the increasing prevalence of ALS and similar neurodegenerative disorders, successful outcomes could lead to broader applications of BCI technology, enhancing Cognixion's competitive edge against existing communication aids. The study's findings may also attract interest from investors and partners in the healthcare technology space, particularly those focused on neurodegenerative diseases and assistive devices.
Indication: ALS (Amyotrophic Lateral Sclerosis)
Modality: medical device
Target: Brain-Computer Interface (BCI) technology for communication in late-stage ALS patients.
Sponsor: Cognixion
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Brain-Computer Interface (BCI) technology for communication in late-stage ALS patients.
View original source fields
Condition raw: ALS (Amyotrophic Lateral Sclerosis)
Condition normalized: ALS (Amyotrophic Lateral Sclerosis)
Modality raw: medical device
Modality normalized: medical device
Target raw: Brain-Computer Interface (BCI) technology for communication in late-stage ALS patients.
Target normalized: Brain-Computer Interface (BCI) technology for communication in late-stage ALS patients.